Parexel and Partex Announce Alliance Leveraging Artificial Intelligence and Big Data

Parexel has announced a preferred strategic alliance with Partex designed to leverage artificial intelligence (AI)-powered solutions.

Under the alliance, clinical trial execution by the Partex group of companies will be managed by Parexel as the preferred CRO provider. Parties will also collaborate on improving clinical trial execution for customers through the Partex-validated AI platform, adding to and expanding Parexel’s existing AI tools and capabilities.

"One of the biggest and most complex challenges in drug development is anticipating the investigational therapies that will be safe and effective treatment options,” said Jamie Macdonald, CEO of Parexel. “Our innovative alliance with Partex helps to address this challenge by bringing to the forefront those assets with the strongest probability of clinical success, in turn enabling customers to focus their time and resources where it is most beneficial to patients.”

"By combining Partex's cutting-edge AI capabilities with Parexel's renowned clinical research expertise, we aim to accelerate the delivery of safe and effective therapies to patients worldwide, ultimately transforming the biopharmaceutical landscape,” added Gunjan Bhardwaj, PhD, CEO, Partex. “We eagerly anticipate the unveiling of new value-generating approaches and groundbreaking innovations resulting from this collaboration.”

Reference

Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development. (2023, August 15). Parexel.